Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/lilly-alzheimers-med-glides-out-leqembi-slipstream-toward-fda-turbulence-adcomm-request
https://www.fiercepharma.com/pharma/eisai-biogens-injectable-leqembi-delayed-fda-asks-more-data
https://pharmaphorum.com/news/test-could-give-early-warning-motor-neuron-disease
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-does-not-refer-eisai-biogen-alzheimers-drug-meeting-notes-2024-03-22/
https://www.fiercebiotech.com/biotech/new-fda-guidelines-consider-amyloid-reduction-reasonably-likely-predict-clinical-benefit
https://investors.biogen.com/news-releases/news-release-details/biogen-participate-stifel-2024-virtual-cns-days
https://investors.biogen.com/news-releases/news-release-details/eisai-host-annual-information-meeting-update-leqembir-lecanemab
https://www.globenewswire.com//news-release/2024/03/06/2841312/0/en/New-Biomarker-Data-Add-Further-Evidence-Supporting-the-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-after-Gene-Therapy.html